Population-level antibiotic treatment policies in the setting of antibiotic resistance: A mathematical model of mass treatment of Helicobacter pylori in Mexico by Alarid-Escudero, Fernando
Population-level antibiotic treatment policies in the setting of antibiotic resistance: A mathematical model of
mass treatment of Helicobacter pylori in Mexico
F. Alarid-Escudero, PhD,1 E. A. Enns, PhD,1 R. F. Maclehose, PhD,1 J. Parsonnet, PhD,2 J. Torres, PhD,3 K. M. Kuntz, ScD1
1University of Minnesota School of Public Health, 2Stanford University, 3Mexican Social Security Institute
Background
Helicobacter pylori (H. pylori)
I A bacterium found in the human stomach
I One of the most prevalent chronic bacterial
infection in the world (50%)
I Strongest known biological risk factor for
gastric cancer
Transmission & Persistence of H. pylori
I Infection usually occurs early in childhood and
risk seems to decrease with age
I Individuals who do not receive treatment generally
have life-long infections
H. pylori treatment and resistance
I Infection can be cleared with antibiotics but
these can induce antibiotic resistance (ABR)
I ABR reduces the effectiveness of treatment and
represents one of the greatest emerging global
health threats
Objectives
I To develop an age-structured transmission model
of H. pylori infection in Mexico that includes both
sensitive and resistant strains
I To evaluate the impact of population-based
antibiotic treatment policies on H. pylori infection
and ABR in Mexico using a transmission model:
. No mass treatment
. Three clarithromycin-based antibiotic treatment
policies assumed to be implemented in 2018:
1. Treat children only (AB 2-6 year-olds)
2. Treat older adults only (AB 40+ year-olds)
3. Treat everyone regardless of age (AB all)
Mathematical model: System of ordinary differential equations (ODE)
Age-specific susceptible-infected-susceptible (SIS) model
with resistance
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Table: Description of variables and parameters
Symbol Description
State variables
S0 Susceptible with NO treatment
S1 Susceptible with treatment
I0w Infected with sensitive strain and NO treatment
I0r Infected with resistant strain and NO treatment
I1r Infected with resistant strain and treatment
Ir = I0r + I1r
Parameters
b Birth rate
β Mixing matrix
ψ Antibiotic treatment policy
α Background use of antibitioc
1/γ Average length of treatment (14 days)
σ
Probability that treatment induces
mutation on sensitive strains and
therefore does not clear colonization
Mixing matrix
I Who-acquires-infection-from-whom (WAIFW) matrix:
Divided the population into N = 6 discrete age classes:
[0,2), [2,6), [6,12), [12,19), [19,45), [45,70)
β =

β1 β1 β1 β4 β5 β6
β1 β2 β3 β4 β5 β6
β1 β3 β3 β4 β5 β6
β4 β4 β4 β4 β5 β6
β5 β5 β5 β5 β5 β6
β6 β6 β6 β6 β6 β6

I Estimated via maximum likelihood
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Results
Impact of different antibiotic mass-treatment policies on
prevalence of H. pylori infection and resistance
Introduction Antibiotic
Policy
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No Policy
Outcome Infection Resistance
I In the absence of a mass-treatment policy, our
model predicts infection begins to rise in 2022
I After the first year of implementation, policy 3 (AB
all) decreases infection by 21% but increases ABR
by 57%
I The decrease in infection relative to the increase in
ABR for policy 3 (AB all) is 37%, it’s highest for
policy 2 (AB 40+ year-olds), 39%, and lowest for
policy 1 (AB 2-6 year-olds), 23%
I These results agree across all scenarios considered in
sensitivity analysis for different WAIFW matrices and
antibiotic treatment background use
Conclusions
I In general, any mass-treatment policy will have a
greater effect on increasing resistance than on
reducing infection
I As the proportion of resistant strains increases and
becomes more prevalent than sensitive strains,
infection starts rising again
I Policy decisions will need to balance the costs of
increased future resistance against short-term
reductions in prevalence
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